Robbins LLP Urges CAPR Stockholders to Contact the Firm for Information About the Class Action Against Capricor Therapeutics, Inc.

Robbins LLP issued a shareholder-solicitation notice regarding Capricor Therapeutics, advising investors of a filed class action lawsuit. The complaint alleges the company misled investors regarding the FDA approval path for its lead candidate Deramiocel, specifically concerning undisclosed changes to the statistical analysis plan.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.